The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents

Wenjie Jessie Lu, Cong Xu, Zifan Pei, Abdelrahman S. Mayhoub, Mark Cushman, David A. Flockhart

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

To improve the treatment of breast cancer, there has been a need for alternative aromatase inhibitors (AIs) that bring about adequate aromatase inhibition, while limiting side effects. Since two tamoxifen metabolites have been documented as AIs, we tested a wide range of tamoxifen metabolites on aromatase in order to better understand structural interactions with aromatase and constructed structure-function relationships as a first step toward the development of novel inhibitors. The ability of ten tamoxifen metabolites to inhibit recombinant aromatase (CYP19) was tested using microsomal incubations. The selectivity of the most potent aromatase inhibitor identified, norendoxifen, was characterized by studying its ability to inhibit CYP450 enzymes important in clinical drug-drug interactions, including CYP2B6, 2C9, 2C19, 2D6, and 3A. Computerized molecular docking with the X-ray crystallographic structure of aromatase was used to describe the detailed biochemical interactions involved. The inhibitory potency order of the tested compounds was as follows: norendoxifen ≫ 4,4′-dihydroxy-tamoxifen > endoxifen > N-desmethyl-tamoxifen, N-desmethyl-4′-hydroxy-tamoxifen, tamoxifen-N-oxide, 4′-hydroxy-tamoxifen, N-desmethyl-droloxifene > 4-hydroxy-tamoxifen, tamoxifen. Norendoxifen inhibited recombinant aromatase via a competitive mechanism with a K i of 35 nM. Norendoxifen inhibited placental aromatase with an IC 50 of 90 nM, while it inhibited human liver CYP2C9 and CYP3A with IC 50 values of 990 and 908 nM, respectively. Inhibition of human liver CYP2C19 by norendoxifen appeared even weaker. No substantial inhibition of CYP2B6 and CYP2D6 by norendoxifen was observed. These data suggest that multiple metabolites of tamoxifen may contribute to its action in the treatment of breast cancer via aromatase inhibition. Most of all, norendoxifen may be able to serve as a potent and selective lead compound in the development of improved therapeutic agents. The range of structures tested in this study and their pharmacologic potencies provide a reasonable pharmacophore upon which to build novel AIs.

Original languageEnglish
Pages (from-to)99-109
Number of pages11
JournalBreast Cancer Research and Treatment
Volume133
Issue number1
DOIs
StatePublished - May 2012

Fingerprint

Aromatase Inhibitors
Aromatase
Tamoxifen
Therapeutics
Breast Neoplasms
N,N-didesmethyl-4-hydroxytamoxifen
Lead
Cytochrome P-450 CYP3A
Cytochrome P-450 CYP2D6
Liver
Drug Interactions
X-Rays

Keywords

  • Aromatase inhibitor
  • Breast cancer
  • Endoxifen
  • Estrogen
  • Norendoxifen
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents. / Lu, Wenjie Jessie; Xu, Cong; Pei, Zifan; Mayhoub, Abdelrahman S.; Cushman, Mark; Flockhart, David A.

In: Breast Cancer Research and Treatment, Vol. 133, No. 1, 05.2012, p. 99-109.

Research output: Contribution to journalArticle

Lu, Wenjie Jessie ; Xu, Cong ; Pei, Zifan ; Mayhoub, Abdelrahman S. ; Cushman, Mark ; Flockhart, David A. / The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents. In: Breast Cancer Research and Treatment. 2012 ; Vol. 133, No. 1. pp. 99-109.
@article{7f666d9b33a643d9b109b3c2cd32aebe,
title = "The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents",
abstract = "To improve the treatment of breast cancer, there has been a need for alternative aromatase inhibitors (AIs) that bring about adequate aromatase inhibition, while limiting side effects. Since two tamoxifen metabolites have been documented as AIs, we tested a wide range of tamoxifen metabolites on aromatase in order to better understand structural interactions with aromatase and constructed structure-function relationships as a first step toward the development of novel inhibitors. The ability of ten tamoxifen metabolites to inhibit recombinant aromatase (CYP19) was tested using microsomal incubations. The selectivity of the most potent aromatase inhibitor identified, norendoxifen, was characterized by studying its ability to inhibit CYP450 enzymes important in clinical drug-drug interactions, including CYP2B6, 2C9, 2C19, 2D6, and 3A. Computerized molecular docking with the X-ray crystallographic structure of aromatase was used to describe the detailed biochemical interactions involved. The inhibitory potency order of the tested compounds was as follows: norendoxifen ≫ 4,4′-dihydroxy-tamoxifen > endoxifen > N-desmethyl-tamoxifen, N-desmethyl-4′-hydroxy-tamoxifen, tamoxifen-N-oxide, 4′-hydroxy-tamoxifen, N-desmethyl-droloxifene > 4-hydroxy-tamoxifen, tamoxifen. Norendoxifen inhibited recombinant aromatase via a competitive mechanism with a K i of 35 nM. Norendoxifen inhibited placental aromatase with an IC 50 of 90 nM, while it inhibited human liver CYP2C9 and CYP3A with IC 50 values of 990 and 908 nM, respectively. Inhibition of human liver CYP2C19 by norendoxifen appeared even weaker. No substantial inhibition of CYP2B6 and CYP2D6 by norendoxifen was observed. These data suggest that multiple metabolites of tamoxifen may contribute to its action in the treatment of breast cancer via aromatase inhibition. Most of all, norendoxifen may be able to serve as a potent and selective lead compound in the development of improved therapeutic agents. The range of structures tested in this study and their pharmacologic potencies provide a reasonable pharmacophore upon which to build novel AIs.",
keywords = "Aromatase inhibitor, Breast cancer, Endoxifen, Estrogen, Norendoxifen, Tamoxifen",
author = "Lu, {Wenjie Jessie} and Cong Xu and Zifan Pei and Mayhoub, {Abdelrahman S.} and Mark Cushman and Flockhart, {David A.}",
year = "2012",
month = "5",
doi = "10.1007/s10549-011-1699-4",
language = "English",
volume = "133",
pages = "99--109",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents

AU - Lu, Wenjie Jessie

AU - Xu, Cong

AU - Pei, Zifan

AU - Mayhoub, Abdelrahman S.

AU - Cushman, Mark

AU - Flockhart, David A.

PY - 2012/5

Y1 - 2012/5

N2 - To improve the treatment of breast cancer, there has been a need for alternative aromatase inhibitors (AIs) that bring about adequate aromatase inhibition, while limiting side effects. Since two tamoxifen metabolites have been documented as AIs, we tested a wide range of tamoxifen metabolites on aromatase in order to better understand structural interactions with aromatase and constructed structure-function relationships as a first step toward the development of novel inhibitors. The ability of ten tamoxifen metabolites to inhibit recombinant aromatase (CYP19) was tested using microsomal incubations. The selectivity of the most potent aromatase inhibitor identified, norendoxifen, was characterized by studying its ability to inhibit CYP450 enzymes important in clinical drug-drug interactions, including CYP2B6, 2C9, 2C19, 2D6, and 3A. Computerized molecular docking with the X-ray crystallographic structure of aromatase was used to describe the detailed biochemical interactions involved. The inhibitory potency order of the tested compounds was as follows: norendoxifen ≫ 4,4′-dihydroxy-tamoxifen > endoxifen > N-desmethyl-tamoxifen, N-desmethyl-4′-hydroxy-tamoxifen, tamoxifen-N-oxide, 4′-hydroxy-tamoxifen, N-desmethyl-droloxifene > 4-hydroxy-tamoxifen, tamoxifen. Norendoxifen inhibited recombinant aromatase via a competitive mechanism with a K i of 35 nM. Norendoxifen inhibited placental aromatase with an IC 50 of 90 nM, while it inhibited human liver CYP2C9 and CYP3A with IC 50 values of 990 and 908 nM, respectively. Inhibition of human liver CYP2C19 by norendoxifen appeared even weaker. No substantial inhibition of CYP2B6 and CYP2D6 by norendoxifen was observed. These data suggest that multiple metabolites of tamoxifen may contribute to its action in the treatment of breast cancer via aromatase inhibition. Most of all, norendoxifen may be able to serve as a potent and selective lead compound in the development of improved therapeutic agents. The range of structures tested in this study and their pharmacologic potencies provide a reasonable pharmacophore upon which to build novel AIs.

AB - To improve the treatment of breast cancer, there has been a need for alternative aromatase inhibitors (AIs) that bring about adequate aromatase inhibition, while limiting side effects. Since two tamoxifen metabolites have been documented as AIs, we tested a wide range of tamoxifen metabolites on aromatase in order to better understand structural interactions with aromatase and constructed structure-function relationships as a first step toward the development of novel inhibitors. The ability of ten tamoxifen metabolites to inhibit recombinant aromatase (CYP19) was tested using microsomal incubations. The selectivity of the most potent aromatase inhibitor identified, norendoxifen, was characterized by studying its ability to inhibit CYP450 enzymes important in clinical drug-drug interactions, including CYP2B6, 2C9, 2C19, 2D6, and 3A. Computerized molecular docking with the X-ray crystallographic structure of aromatase was used to describe the detailed biochemical interactions involved. The inhibitory potency order of the tested compounds was as follows: norendoxifen ≫ 4,4′-dihydroxy-tamoxifen > endoxifen > N-desmethyl-tamoxifen, N-desmethyl-4′-hydroxy-tamoxifen, tamoxifen-N-oxide, 4′-hydroxy-tamoxifen, N-desmethyl-droloxifene > 4-hydroxy-tamoxifen, tamoxifen. Norendoxifen inhibited recombinant aromatase via a competitive mechanism with a K i of 35 nM. Norendoxifen inhibited placental aromatase with an IC 50 of 90 nM, while it inhibited human liver CYP2C9 and CYP3A with IC 50 values of 990 and 908 nM, respectively. Inhibition of human liver CYP2C19 by norendoxifen appeared even weaker. No substantial inhibition of CYP2B6 and CYP2D6 by norendoxifen was observed. These data suggest that multiple metabolites of tamoxifen may contribute to its action in the treatment of breast cancer via aromatase inhibition. Most of all, norendoxifen may be able to serve as a potent and selective lead compound in the development of improved therapeutic agents. The range of structures tested in this study and their pharmacologic potencies provide a reasonable pharmacophore upon which to build novel AIs.

KW - Aromatase inhibitor

KW - Breast cancer

KW - Endoxifen

KW - Estrogen

KW - Norendoxifen

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=84860321539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860321539&partnerID=8YFLogxK

U2 - 10.1007/s10549-011-1699-4

DO - 10.1007/s10549-011-1699-4

M3 - Article

VL - 133

SP - 99

EP - 109

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -